Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Westpac (ASX: WBC) Q1 Profit Rises 6% as Lending Growth and Treasury Income Strengthen Earnings 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
GE Aerospace Expands Singapore Engine Repair Hub with Automation and AI to Tackle Aviation Bottlenecks 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval 
YARDLEY, Pa., Nov. 08, 2017 -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ENT and allergy specialists, today announced that Chief Executive Officer Peter Miller will present at the Jefferies 2017 London Healthcare Conference on November 15, 2017, at 11:40 am ET/4:40 pm GMT. To listen to a webcast of the presentation live, please visit the Investors page of the Optinose website. A replay of the webcast will be available for 90 days following the conclusion of the event.
About Optinose®
Optinose is a specialty pharmaceutical company on a mission to improve lives with a focus on patients cared for by ear, nose and throat (ENT) and allergy specialists. The Company’s first two products rely on our patented Exhalation Delivery Systems (EDS), which is capable of deep intranasal deposition of medication. These exhalation delivery systems enable the creation of products with potential for meaningful new clinical benefits. Optinose developed its first product, Onzetra® Xsail® (sumatriptan nasal powder), through the completion of Phase 3 and subsequently out-licensed the product to Otsuka Pharmaceutical Co., Ltd. Onzetra Xsail received FDA approval and was launched in the U.S. in 2016. The Company’s second product, XHANCE (fluticasone propionate) nasal spray, is approved for the treatment of nasal polyps in patients 18 years of age and older and is in development for the treatment of chronic sinusitis. Subsequent Optinose pipeline products will aim to serve the needs of patients treated by ENT and allergy specialists and are expected to include products using EDS as well as other technologies. The Company is also currently engaged in the early development of products for neurologic orphan diseases for which the “nose-to-brain” application of an EDS may enable improved treatment. This includes OPN-300 (Prader-Willi Syndrome, autism, and others) and OPN-21 (narcolepsy and others). Optinose has corporate offices in the U.S., U.K. and Norway. To learn more, please visit www.optinose.com.
Optinose Media Contact
Kate Traynor, Sloane & Company
[email protected]
212.446.1871
